Loading…
Loading…
VIR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VIR and 80,000+ other tickers.
See exactly how VIR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VIR and 80,000+ other tickers.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of…
Bank of New York Mellon Corp bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 694,374 shares of the company's stock, valued at approximately $7,076,000. Bank of
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New York. A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, In.
Algert Global LLC grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ: VIR) by 64.6% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 804,977 shares of the company's stock after buying an additional 315,969 shares during the period. Algert Global LLC owned
ADAR1 Capital Management LLC bought a new stake in Vir Biotechnology, Inc. (NASDAQ: VIR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,456,677 shares of the company's stock, valued at approximately $25,034,000. Vir Biotechnology comprises 1.1% of ADAR1
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript